Tue, 17 Sep 2019 12:00:00 EDT Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer Conditions: Pre-Eclampsia; Frozen Embryo Transfer Intervention: Procedure: FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE Sponsors: Instituto Valenciano de Infertilidad, IVI VALENCIA; IVI Bilbao; IVI Barcelona; IVI Madrid; IVI Sevilla; IVI Vigo; IVI Roma; Hospital Universitario La Paz Not yet recruiting
Tue, 17 Sep 2019 12:00:00 EDT The Effect of Different Training Programs on Patients With Chronic Diseases Conditions: Hypertension; Hypertension Complicated With Type 2 Diabetes; Walking; Chinese Square Dancing Interventions: Behavioral: Walking; Behavioral: Chinese square dancing group; Behavioral: Control group Sponsors: Beijing Sport Uninversity; Peking University Recruiting
Tue, 17 Sep 2019 12:00:00 EDT ´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2. Condition: Diabetes Mellitus, Type II Intervention: Behavioral: Walk@WorkApp-Diab Sponsors: Jordi Gol i Gurina Foundation; Instituto de Salud Carlos III; Consorci Hospitalari de Vic; Institut Català de la Salut; University of Vic - Central University of Catalonia; Puerta de Hierro University Hospital Recruiting
Mon, 16 Sep 2019 12:00:00 EDT Depression and Pain Perseverance Through Empowered Recovery Intervention Conditions: Pain; Depressive Symptoms; Frailty; Aging Intervention: Behavioral: DAPPER Sponsors: Johns Hopkins University; Robert Wood Johnson Foundation; National Institute on Aging (NIA) Not yet recruiting
Mon, 16 Sep 2019 12:00:00 EDT Targeted Lifestyle Change Group Prenatal Care Conditions: Pregnancy; Gestational Diabetes Intervention: Behavioral: TLC Group Prenatal Care Sponsor: Washington University School of Medicine Not yet recruiting
Mon, 16 Sep 2019 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
FDA approves first treatment for patients with rare type of lung disease FDA approves Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.
